Table 3 Crude estimates of mortality, length of stay, and organ dysfunction stratified by study period
From: Intensive insulin therapy and mortality in critically ill patients
| Â | Period I (n = 2,366) 1 Mar 01 to 28 Feb 02 | Period II (n = 3,322) 1 Mar 02 to 30 Jun 03 | Period III (n = 4,786) 1 Jul 03 to 28 Feb 05 | P valuea |
|---|---|---|---|---|
ICU mortality, n (%) | 214 (9.04) | 358 (10.78) | 465 (9.75) | 0.086 |
OR (95% CI) of ICU mortality | 1.00 | 1.21 (1.01, 1.46) | 1.09 (0.92, 1.29) | Â |
Hospital mortality, n (%) | 334 (14.12) | 522 (15.71) | 686 (14.39) | 0.157 |
OR (95% CI) of hospital mortality | 1.00 | 1.13 (0.97, 1.32) | 1.02 (0.88, 1.17) | Â |
Patients in ICU <3 days | n = 1,296 | n = 1,829 | n = 2,678 | Â |
ICU mortality in patients in ICU <3 days, n (%) | 76 (5.86) | 128 (7.0) | 181 (6.76) | 0.428 |
Hospital mortality in patients in ICU <3 days, n (%) | 122/1,174 (9.4) | 203/1,829 (11.1) | 283/2,678 (10.6) | 0.310 |
Hospital mortality in patients with hypoglycemia <40 mg/dL, n (%) | 9/24 (38) | 23/53 (43) | 41/103 (40) | 0.863 |
Average SOFA score, mean ± SDb | 1.65 (2.00) | 1.77 (2.09) | 1.62 (1.98) | <0.01 |
Maximum SOFA score, mean ± SDb | 2.82 (2.85) | 2.96 (2.99) | 2.74 (2.84) | 0.004 |